Register now
WEBINAR
Digital Decentralized Clinical Trials (DDCT): How will digital solutions change the way clinical trials will be conducted in the future?
November 12, 2021

Frontiers Health roundup panel discussion with key thought leaders on: How will digital solutions change the way clinical trials will be conducted in the future?

By Stela Nikolova, Research2Guidance

Digital decentralized clinical trial (DDCTs) solutions have become increasingly attractive and the investment into DDCT companies has tripled since the beginning of the pandemic. It is expected that from 2020 to 2026, the share of the total clinical trial market captured by DDCT providers in North America and Europe will increase from 2.8% to 21.3%.

At this years’ Frontiers Health event in Milan, Research2Guidance’s team together with key decision-makers from two innovative DCT companies, a novel DTx solution provider, and a leading Pharma company delved into digital decentralized market landscape and six main business models, the types of digital solutions and in what ways digital tools change how clinical trials are conducted, market trends & how can trial sponsors benefit from DDCTs solutions.

On November 12, 2021, Research2Guidance hosted a virtual Digital Decentralized Clinical Trials panel session at Frontiers Health with global top market players as guests that exchanged views and opinions on how will digital tools change the way clinical trials will be conducted in the future and explored the current status and trends of the DDCT market in North America and Europe.

The workshop-like discussion was stimulated by a short introduction from Ralf Jahns, MD of Research2Guidance and the session moderator, followed by key digital decentralized clinical trials market and main business models insights, as well as the ways innovative tools are used throughout the research process, all data-driven metrics and analyses from R2G’s latest report on “The Digital Decentralized Clinical Trial (DDCTs) Solutions Market 2018 – 2026” presented by Isabel Cassidy-Soto, Digital Health Consultant, Research2Guidance.

Cases and highly insightful market points were shared by

  • Paul O’Donohoe, Senior Director, eCOA Product and Science, Medidata
  • Katri Langel, Sr. Program Development, Europe, Curebase
  • Stefka Lysk, Head of Clinical Development and Operations, M-sense Migräne by Newsenselab
  • Karl-Ludwig Radek, Ass. Director, EMEA Strategic Account Lead, Janssen Pharmaceutical

that demonstrated unique business models and service offerings, as well as a sponsor trial view about DCT’s role, benefits and cons of DCT value proposition. The dynamic market picture was completed by an engaging discussion.

The digital decentralized clinical trials market is very interesting and dynamic. Decentralized trial designs leverage innovative tools, such as telehealth, mobile applications to allow for remote data collection and patient participation, in contrast to traditional trial designs involving a physical site for all activities.

Digital decentralized clinical trials solutions and services have experienced a boom due to the COVID-19 pandemic. DCT has made sponsors and market players rethink how clinical trials are designed and how they are executed. To be successful there is a need for collaboration between providers and pharma, as well as sponsors (different Pharma companies) to join their forces.

The market for decentralised clinical trials will grow by almost $8 billion (38.5% CAGR) from 2021 to 2026. The revenue from the DDCT market will reach $9.13 billion by 2026.

About Curebase
Curebase is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Our vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors. This is made possible through a unique suite of tools Curebase’s has designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or other places in their community.  

This starts with Curebase’s leading decentralized clinical trial software platform that is an all-in-one, purpose built eClinical software system, with every tool needed to manage and collect data for decentralized clinical trials. This includes ePRO, eCOA, eConsent, Telemedicine, and much more. Curebase also offers a virtual research site, complete with virtual investigators, research coordinators, mobile nursing, and other healthcare staff that administer care to patients where convenient for them, just like any other research site, but with the ability to stand up anywhere and with greater patient convenience and reach. Notably, Curebase is the pioneer of the “BYOP” or Bring Your Own Physician model, allowing patients to use their own doctors to participate in clinical trials. 

We are reinventing a $45B market, enabling drug and device companies to increase the volume, quality, and speed of data collection regardless of patients’ physical location. COVID-19 tailwinds have created massive demand for telemedicine and home-based trials, with two new FDA guidance letters and industry-wide adoption of remote remote research that will only accelerate in the years to come. You can learn more about Curebase and our next stage of growth in Crunchbase, Fierce Biotech, and MedCity News!

You can learn more in a 1-1 meeting with Curebase.
Request a Meeting
Or, subscribe to our blog and other educational updates.
Reserve your spot today!

Curebase Webinar

Digital Decentralized Clinical Trials (DDCT): How will digital solutions change the way clinical trials will be conducted in the future?

November 12, 2021
Featured speaker:
Katri Langel
Senior Program Director, Europe, Curebase
Katri Langel
Senior Program Director, Europe, Curebase
Nov 12, 2021 9:00 AM
EST
free
About the Webinar
Collaborate with patient representatives for software configuration and user testing
Assist patients along their treatment journey with patient-centric software and communication tools
Closely monitor data in real-time to gain actionable insights into the patient experience

Frontiers Health roundup panel discussion with key thought leaders on: How will digital solutions change the way clinical trials will be conducted in the future?

By Stela Nikolova, Research2Guidance

Digital decentralized clinical trial (DDCTs) solutions have become increasingly attractive and the investment into DDCT companies has tripled since the beginning of the pandemic. It is expected that from 2020 to 2026, the share of the total clinical trial market captured by DDCT providers in North America and Europe will increase from 2.8% to 21.3%.

At this years’ Frontiers Health event in Milan, Research2Guidance’s team together with key decision-makers from two innovative DCT companies, a novel DTx solution provider, and a leading Pharma company delved into digital decentralized market landscape and six main business models, the types of digital solutions and in what ways digital tools change how clinical trials are conducted, market trends & how can trial sponsors benefit from DDCTs solutions.

On November 12, 2021, Research2Guidance hosted a virtual Digital Decentralized Clinical Trials panel session at Frontiers Health with global top market players as guests that exchanged views and opinions on how will digital tools change the way clinical trials will be conducted in the future and explored the current status and trends of the DDCT market in North America and Europe.

The workshop-like discussion was stimulated by a short introduction from Ralf Jahns, MD of Research2Guidance and the session moderator, followed by key digital decentralized clinical trials market and main business models insights, as well as the ways innovative tools are used throughout the research process, all data-driven metrics and analyses from R2G’s latest report on “The Digital Decentralized Clinical Trial (DDCTs) Solutions Market 2018 – 2026” presented by Isabel Cassidy-Soto, Digital Health Consultant, Research2Guidance.

Cases and highly insightful market points were shared by

  • Paul O’Donohoe, Senior Director, eCOA Product and Science, Medidata
  • Katri Langel, Sr. Program Development, Europe, Curebase
  • Stefka Lysk, Head of Clinical Development and Operations, M-sense Migräne by Newsenselab
  • Karl-Ludwig Radek, Ass. Director, EMEA Strategic Account Lead, Janssen Pharmaceutical

that demonstrated unique business models and service offerings, as well as a sponsor trial view about DCT’s role, benefits and cons of DCT value proposition. The dynamic market picture was completed by an engaging discussion.

The digital decentralized clinical trials market is very interesting and dynamic. Decentralized trial designs leverage innovative tools, such as telehealth, mobile applications to allow for remote data collection and patient participation, in contrast to traditional trial designs involving a physical site for all activities.

Digital decentralized clinical trials solutions and services have experienced a boom due to the COVID-19 pandemic. DCT has made sponsors and market players rethink how clinical trials are designed and how they are executed. To be successful there is a need for collaboration between providers and pharma, as well as sponsors (different Pharma companies) to join their forces.

The market for decentralised clinical trials will grow by almost $8 billion (38.5% CAGR) from 2021 to 2026. The revenue from the DDCT market will reach $9.13 billion by 2026.

About Curebase
Curebase is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Our vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors. This is made possible through a unique suite of tools Curebase’s has designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or other places in their community.  

This starts with Curebase’s leading decentralized clinical trial software platform that is an all-in-one, purpose built eClinical software system, with every tool needed to manage and collect data for decentralized clinical trials. This includes ePRO, eCOA, eConsent, Telemedicine, and much more. Curebase also offers a virtual research site, complete with virtual investigators, research coordinators, mobile nursing, and other healthcare staff that administer care to patients where convenient for them, just like any other research site, but with the ability to stand up anywhere and with greater patient convenience and reach. Notably, Curebase is the pioneer of the “BYOP” or Bring Your Own Physician model, allowing patients to use their own doctors to participate in clinical trials. 

We are reinventing a $45B market, enabling drug and device companies to increase the volume, quality, and speed of data collection regardless of patients’ physical location. COVID-19 tailwinds have created massive demand for telemedicine and home-based trials, with two new FDA guidance letters and industry-wide adoption of remote remote research that will only accelerate in the years to come. You can learn more about Curebase and our next stage of growth in Crunchbase, Fierce Biotech, and MedCity News!

You can learn more in a 1-1 meeting with Curebase
Book a meeting
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States

Register for Webinar

We'd love to hear from you, whether a Sponsor interested in running a study with us, a provider looking to get involved in clinical research, or patients interested in our studies. Fill out your information below and one of our team members will be in touch.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.